)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Mauna Kea Technologies
Mauna Kea Technologies (ALMKT) investor relations material
Mauna Kea Technologies Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary20 Oct, 2026
Executive summary
9M 2026 sales reached €4,409K, up 21% reported and 24% at constant exchange rates; excluding China, the highest 9M sales in six years.
Recurring revenue rose 17% at constant exchange rates to €2.9m; 10 systems sold versus six in 9M 2025.
Q3 sales fell 10% reported and 11% at constant exchange rates amid temporary U.S. staffing gaps and system shipments scheduled for Q4.
Financial highlights
9M product sales totaled €4,409K versus €3,645K in 9M 2025, up 21% reported and 24% at constant exchange rates.
Q3 product sales were €1,206K versus €1,343K, down 10% reported and 11% at constant exchange rates.
Recurring sales from probes, pay-per-use and services rose 17% at constant exchange rates to €2.9m, representing 67% of 9M sales.
U.S. sales were €2,938K, up 1%; EMEA and Rest of World sales were €1,471K, up 128%.
Outlook and guidance
Q4 is historically the strongest quarter; Q4 2025 sales were €1,944K, and the systems pipeline is mostly weighted to Q4.
Q4 opportunities include pancreatic-lesion systems, U.S. systems nearing maintenance end, and international pipeline, including Turkey and the Middle East.
All four U.S. territories were staffed by October, each with a Territory Manager and Clinical Associate.
TaeWoong’s dedicated team is targeting more than 200 potential accounts; additional partnerships are under consideration to expand Cellvizio’s reach.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mauna Kea Technologies
- H1 sales grew 44% at CER as CellTolerance and pancreatic adoption fueled expansion.ALMKT
Corporate presentation - CellTolerance-led revenue rose 37%; forecasts support operations through end-2027.ALMKTH1 2026
- Sales up 44% in H1 2026, driven by U.S. probe and CellTolerance growth, targeting profitability.ALMKTQ2 2026 TU
- Rapid clinical adoption and high-margin growth position the platform for global expansion and profitability.ALMKTCorporate presentation
- Cellvizio's clinical innovation and commercial momentum fuel accelerated growth and profitability.ALMKTCorporate presentation
- Debt dropped 69%, net profit hit €10.8M, and sales momentum accelerated into 2026.ALMKTH2 2025
- Sales rose 68% at CER, driven by U.S. and international demand and major debt reduction.ALMKTQ1 2026 TU
- Revenue fell 5% as US sales rose and safeguard plan targets debt reduction, supporting growth.ALMKTH1 2025
- H1 2024 revenue fell 43%, net loss was €4.7M, and Q3 sales rose 24% year-over-year.ALMKTH1 2024 & Q3 2024 TU
Next Mauna Kea Technologies earnings date
H2 202622 Apr, 2027
Mauna Kea Technologies
Next Mauna Kea Technologies earnings date
H2 202622 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Mauna Kea Technologies SA is a French medical device company that specializes in developing and marketing advanced optical biopsy systems. The company's flagship product, Cellvizio, is a probe-based Confocal Laser Endomicroscopy (pCLE) platform. This technology allows physicians to obtain real-time, high-resolution cellular images during endoscopic procedures, primarily for detecting abnormalities in the gastrointestinal and pulmonary tracts, particularly in cancer patients. The Cellvizio system is designed to improve diagnostic accuracy and support more immediate treatment decisions, with applications across multiple medical specialties. Mauna Kea Technologies is headquartered in Paris, France, and its shares are listed on the Euronext Paris.